Cara Therapeutics
(NASDAQ) CARA
This security has been delisted. This page is retained for historical reference.
CARA News
Is Cara Therapeutics a Buy?
3 Pot Stocks Worth a Second Look
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowCARA Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-64%
Return on Capital
-2%
Return on Assets
-60%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$26.75M
EBITDA
$26.75M
Operating Cash Flow
$23.50M
Capital Expenditure
$0.00
Free Cash Flow
$23.50M
Cash & ST Invst.
$30.81M
Total Debt
$201.00K
Cara Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
10
N/A
Net Income
$6.80M
-38.7%
EBITDA
$7.05M
N/A
Quarterly Fundamentals
Net Cash
$24.81M
-27.5%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
-100.0%
Long Term Debt
$54.00K
N/A
Short Term Debt
$120.00K
N/A
Return on Assets
-59.80%
N/A
Return on Invested Capital
-2.02%
N/A
Free Cash Flow
$5.86M
-24.9%
Operating Cash Flow
$5.86M
-24.9%